Two months have lapsed since the FDA warned that the antifibrinolytic drug aprotinin (Trasylol) could cause renal failure, congestive heart failure, stroke, and death. Yet significant questions about the drug's safety profile continue to swirl in part by one researcher's alleged failure to provide full access to his data and looming questions about Bayer HealthCare's admitted blunder in not immediately sharing data from a retrospective study."Bayer's failure to submit the data, or to even make it known that they were doing the study, is simply inexcusable," said a researcher with the Toronto-based University Health Network who led one of the two aprotinin studies that raised concerns about the drug's safety. (Scientist)
